326 related articles for article (PubMed ID: 18254053)
1. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
[TBL] [Abstract][Full Text] [Related]
2. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
[TBL] [Abstract][Full Text] [Related]
3. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD003376. PubMed ID: 18254018
[TBL] [Abstract][Full Text] [Related]
4. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Zheng C; Peterson J; Tugwell P; Liu W
Cochrane Database Syst Rev; 2022 May; 5(5):CD004523. PubMed ID: 35502787
[TBL] [Abstract][Full Text] [Related]
5. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Peterson J; Zheng C; Kelly SE; Shea B; Tugwell P
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD003376. PubMed ID: 38591743
[TBL] [Abstract][Full Text] [Related]
6. Alendronate for fracture prevention in postmenopause.
Holder KK; Kerley SS
Am Fam Physician; 2008 Sep; 78(5):579-81. PubMed ID: 18788232
[TBL] [Abstract][Full Text] [Related]
7. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
8. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
11. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
12. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
13. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
14. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
16. Review of risedronate in the treatment of osteoporosis.
Geusens P; McClung M
Expert Opin Pharmacother; 2001 Dec; 2(12):2011-25. PubMed ID: 11825332
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.
Avenell A; Mak JC; O'Connell D
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD000227. PubMed ID: 24729336
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]